Nextera AS logo — Opening a new arena for drug discovery

Nextera AS

Opening a new arena for drug discovery

Founded 2009 Norway Norway 20 employees Seed Biotechnology, Health Care +1

General Information

Company Name Nextera AS
Founded Year 2009
Location Norway Norway +1
Founders / Decision Makers
Team member Team member
Employees 20
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Seed
Social

Get notified when Nextera AS moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Nextera AS

Nextera AS is a biotechnology startup based in Norway founded in 2009. The company's slogan, "Opening a new arena for drug discovery," reflects its mission to revolutionize therapeutic intervention in autoimmunity, chronic inflammatory disorders, and cancer. Nextera's distinctive approach involves modulating diseases at the core of the escalating immune cascade, thus enabling disease-specific treatments without compromising systemic immunity.

The company's strategy focuses on discovering new targets and developing cognate drugs in collaboration with partners to address complex diseases. Nextera's emphasis on patient-centric solutions entails a deep understanding of diseased tissue and underlying immune repertoires, providing the unique capability to decipher clinical material and intervene accordingly.

Nextera received its Seed Round investment on 01 January 2010 from Birk Venture. With a focus on biotechnology, healthcare, and pharmaceuticals, the company aims to make significant contributions in the field of drug and target discovery.

Taxonomy: Drug discovery, Therapeutic intervention, Autoimmunity, Chronic inflammatory disorders, Cancer treatment, Target discovery, New targets, Cognate drugs, Complex diseases, Therapies development, Immune system modulation, Clinical material analysis, Diseased tissue focus, Immune cascade, Patient-centered approach

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 1
Investor
01 Jan 2010

Nextera AS Alternatives & Competitors

Nextera AS vs

Multilineage immune modulation. The next chapter in autoimmune diseases.

Seed
3 employees
Health Care, Health and Wellness
Nextera AS vs
COUR Pharma
COUR Pharma United States

Reprogramming the immune system to restore health in people suffering from autoimmune diseases

Series A
61 employees
Biotechnology, Health and Wellness
Nextera AS vs

Our R&D platform is focused on developing immune modulating therapeutics for patients with autoimmun...

Grant
4 employees
Biotechnology

FAQ About Nextera AS

Opening a new arena for drug discovery
Nextera AS was founded in 2009.
Nextera AS is headquartered in Norway.
Nextera AS operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Nextera AS has approximately 20 employees.
Nextera AS has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to Nextera AS include Mysthera Therapeutics, COUR Pharma, Phialogics - The immune tolerance company, Larkspur Biosciences, Mestag Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nextera AS and Mysthera Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Nextera AS and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes